Clear Road raised the agency’s value goal on BioNTech (BNTX) to $185 from $181 and retains a Purchase score on the shares after updating the agency’s mannequin to a year-end 2026 valuation following the corporate reporting Q2 outcomes this morning. The corporate stays on observe to report Section 2 dose optimization outcomes from BNT327 research in small cell lung most cancers and triple unfavorable breast most cancers within the second half of 2025, notes the analyst, who calls the corporate’s oncology pipeline “underappreciated.”
-
Make the most of TipRanks Premium at 50% off! Unlock highly effective investing instruments, superior information, and skilled analyst insights that will help you make investments with confidence.
Printed first on TheFly – the last word supply for real-time, market-moving breaking monetary information. Strive Now>>
See the highest shares advisable by analysts >>
Learn Extra on BNTX:
